Noribogaine
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 12-Hydroxyibogamine; Ibogamin-12-ol; O-desmethylibogaine; (-)-Noribogaine; |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Noribogaine (actually O-desmethylibogaine), or 12-hydroxyibogamine, is the principal
Pharmacology
Noribogaine is a potent serotonin reuptake inhibitor,[5] but does not affect the reuptake of dopamine.[6] Unlike ibogaine, noribogaine does not bind to the sigma-2 receptor.[7][8] Similarly to ibogaine, noribogaine acts as a weak NMDA receptor antagonist and binds to opioid receptors.[9] It has greater affinity for each of the opioid receptors than does ibogaine.[10]
Noribogaine is a
arrhythmias and sudden cardiac arrest.[12]
κ-Opioid receptor
Noribogaine has been determined to act as a
β-arrestin pathway.[13] Moreover, due to its very low efficacy on the β-arrestin pathway, noribogaine blocked dynorphin A activation of the pathway (IC50 = 1 μM) and hence functioned as an antagonist of it.[13]
The β-arrestin pathway is thought to be responsible for the
anhedonic effects that are typical of them.[13]
See also
- Ibogamine
- Voacangine
- Tabernanthine
- Coronaridine
- RB-64
- 6'-Guanidinonaltrindole
- Herkinorin
- TRV130
- Nalfurafine
References
- S2CID 40776971.
- S2CID 11416176.
- PMID 11705118.
- PMID 19142057.
- ISBN 978-0-12-800624-5.
- PMID 11303040.
- ISBN 978-1-4406-5024-6.
- ISBN 978-0-12-053206-3.
- ISBN 978-0-471-72760-6.
- S2CID 28001919.
- S2CID 16071274.
- S2CID 7026570.
- ^ PMID 26302653.
- PMID 26377476.